<DOC>
	<DOCNO>NCT00003759</DOCNO>
	<brief_summary>RATIONALE : Drugs use chemotherapy use different way stop tumor cell divide stop grow die . Biological therapy BCG use different way stimulate immune system stop cancer cell grow . It yet know whether AD 32 effective without BCG surgery superficial bladder cancer . PURPOSE : Randomized phase II trial compare effectiveness AD 32 without BCG surgery treat patient newly diagnose recurrent superficial bladder cancer .</brief_summary>
	<brief_title>AD 32 With Without BCG After Surgery Treating Patients With Newly Diagnosed Recurrent Superficial Bladder Cancer</brief_title>
	<detailed_description>OBJECTIVES : - Evaluate efficacy peri-operative intravesical AD 32 alone supplement BCG patient newly diagnose recurrent superficial bladder cancer characterize either high risk low risk base tumor marker p53 pRb . - For low-risk patient , assess efficacy peri-operative AD 32 prevent tumor recurrence . - For high-risk patient , assess efficacy combine intravesical therapy AD 32 administer within 8 hour transurethral resection along BCG decrease incidence tumor progression . - Evaluate systemic exposure urine recovery AD 32 pharmacokinetic analysis subset patient . OUTLINE : This randomize , open-label study . All patient undergo complete transurethral resection remove bladder tumor . AD 32 administer catheter bladder within 8 hour surgery . Patients must hold AD 32 bladder 90 minute . After pathological tumor marker analysis , patient assign low high-risk group define p53 pRb phenotype . - Low risk : Patients carcinoma situ receive BCG catheter bladder weekly 6 week begin 7-21 day treatment AD 32 . Patients assign low-risk group carcinoma situ receive treatment . - High-risk : Patients also receive BCG weekly 6 week weekly 3 week 3 month , 6 month , every 6 month total 3 year first BCG treatment . All patient undergo cystoscopy every 3 month first year every 6 month next 2 year . PROJECTED ACCRUAL : Approximately 200 patient accrue study .</detailed_description>
	<mesh_term>Urinary Bladder Neoplasms</mesh_term>
	<mesh_term>BCG Vaccine</mesh_term>
	<mesh_term>Valrubicin</mesh_term>
	<criteria>DISEASE CHARACTERISTICS : Newly diagnose recurrent ( least 2 occurrence within 12 month ) Ta , multifocal Ta ( least 2 visible tumor ) , stage T1 bladder cancer No carcinoma situ ( Tis ) No T2 great tumor No evidence upper tract ( ureter renal pelvic ) transitional cell carcinoma base intravenous pyelogram perform within 4 month TURB PATIENT CHARACTERISTICS : Age : 18 Performance status : SWOG 02 Life expectancy : Not specify Hematopoietic : WBC great 3,500/mm3 Platelet count great 100,000/mm3 Hepatic : Not specify Renal : Not specify Other : Not pregnant nursing Negative pregnancy test Fertile patient must use effective contraception No prior malignancy within past 5 year except adequately treat basal cell squamous cell skin cancer , carcinoma situ cervix , superficial transitional cell carcinoma bladder PRIOR CONCURRENT THERAPY : Biologic therapy : No concurrent biological response modifier Chemotherapy : No concurrent chemotherapy Endocrine therapy : No concurrent hormonal therapy Radiotherapy : No concurrent radiotherapy Surgery : Not specify</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>November 2002</verification_date>
	<keyword>stage 0 bladder cancer</keyword>
	<keyword>stage I bladder cancer</keyword>
	<keyword>recurrent bladder cancer</keyword>
</DOC>